Overview

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Status:
TERMINATED

Trial end date:
2025-01-15

Target enrollment:

Participant gender:

Summary

This study will determine how nanatinostat is absorbed, modified, and removed from the body (Part A), the amount of nanatinostat that becomes available to the body (Part B), and will evaluate the safety and tolerability of nanatinostat (Part C) in patients with advanced cancers.

Phase:

PHASE1

Details

Lead Sponsor:

Viracta Therapeutics, Inc.

Treatments:

Tablets
Valganciclovir